|11.63||+0.1300||+1.13%||Vol 754.44K||1Y Perf -38.02%|
|Apr 13th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||29.25||Analyst Rating||Strong Buy 1.00|
|Potential %||151.51||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-67/-43/-16||Value Ranking||★★★ 52.22|
|Insiders Value % 3/6/12 mo.||-86/-63/-25||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-86/-59/-30||Income Ranking||— -|
|Market Cap||354.21M||Earnings Rating||Sell|
|Price Range Ratio 52W %||4.20||Earnings Date||6th May 2021|
Today's Price Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||6th May 2021|
|Estimated EPS Next Report||-0.37|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||283.13K|
|Avg. Monthly Volume||288.63K|
|Avg. Quarterly Volume||324.76K|
Cue Biopharma Inc. (NASDAQ: CUE) stock closed at 11.63 per share at the end of the most recent trading day (a 1.13% change compared to the prior day closing price) with a volume of 754.46K shares and market capitalization of 354.21M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 47 people. Cue Biopharma Inc. CEO is Daniel R. Passeri.
The one-year performance of Cue Biopharma Inc. stock is -38.02%, while year-to-date (YTD) performance is -7.03%. CUE stock has a five-year performance of %. Its 52-week range is between 10.75 and 31.69, which gives CUE stock a 52-week price range ratio of 4.20%
Cue Biopharma Inc. currently has a PE ratio of -7.90, a price-to-book (PB) ratio of 4.79, a price-to-sale (PS) ratio of 155.37, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -50.46%, a ROC of -66.50% and a ROE of -64.75%. The company’s profit margin is -%, its EBITDA margin is -1 011.70%, and its revenue ttm is $2.25 Million , which makes it $0.07 revenue per share.
Of the last four earnings reports from Cue Biopharma Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.37 for the next earnings report. Cue Biopharma Inc.’s next earnings report date is 06th May 2021.
The consensus rating of Wall Street analysts for Cue Biopharma Inc. is Strong Buy (1), with a target price of $29.25, which is +151.51% compared to the current price. The earnings rating for Cue Biopharma Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Cue Biopharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Cue Biopharma Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.64, ATR14 : 1.09, CCI20 : -97.00, Chaikin Money Flow : 0.01, MACD : -0.48, Money Flow Index : 18.33, ROC : -5.29, RSI : 48.79, STOCH (14,3) : 36.36, STOCH RSI : 0.72, UO : 50.10, Williams %R : -63.64), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Cue Biopharma Inc. in the last 12-months were: Aaron Fletcher (Buy at a value of $455 919), Anish Suri (Option Excercise at a value of $48 620), Anish Suri (Sold 7 000 shares of value $140 122 ), Cameron Gray (Buy at a value of $151 500), Colin G. Sandercock (Option Excercise at a value of $150 000), Colin G. Sandercock (Sold 20 000 shares of value $400 010 ), Kenneth J. Pienta (Buy at a value of $40 980), Kenneth J. Pienta (Option Excercise at a value of $139 365), Kenneth J. Pienta (Sold 36 433 shares of value $550 641 ), Kerri-Ann Millar (Option Excercise at a value of $0)
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.